Literature DB >> 14644862

Osteocyte viability with glucocorticoid treatment: relation to histomorphometry.

P N Sambrook1, D R Hughes, A E Nelson, B G Robinson, R S Mason.   

Abstract

BACKGROUND: Glucocorticoid induced osteoporosis is a common clinical problem.
OBJECTIVE: To determine the pathophysiology of glucocorticoid induced osteoarthritis at the organ level.
METHODS: Iliac crest biopsy specimens were obtained from nine patients receiving prednisone treatment for rheumatoid arthritis. Osteocyte viability and histomorphometric indices were assessed.
RESULTS: Compared with controls, glucocorticoid treated subjects had reduced trabecular thickness and increased erosion. The number of viable osteocytes was significantly decreased in glucocorticoid treated patients compared with controls.
CONCLUSION: The impaired bone formation, increased erosion and, importantly, loss of viable osteocytes are all likely to contribute to the increased risk of fracture in these patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644862      PMCID: PMC1754416          DOI: 10.1136/ard.2003.008839

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

Review 1.  Bone histomorphometry in glucocorticoid-induced osteoporosis.

Authors:  D W Dempster
Journal:  J Bone Miner Res       Date:  1989-04       Impact factor: 6.741

2.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

3.  Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.

Authors:  Robert S Weinstein; Jin-Ran Chen; Cara C Powers; Scott A Stewart; Reid D Landes; Teresita Bellido; Robert L Jilka; A Michael Parfitt; Stavros C Manolagas
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

4.  Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip.

Authors:  R S Weinstein; R W Nicholas; S C Manolagas
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

5.  Identification of apoptotic changes in osteocytes in normal and pathological human bone.

Authors:  B S Noble; H Stevens; N Loveridge; J Reeve
Journal:  Bone       Date:  1997-03       Impact factor: 4.398

6.  Relationships between osteocyte density and bone formation rate in human cancellous bone.

Authors:  S Qiu; D S Rao; S Palnitkar; A M Parfitt
Journal:  Bone       Date:  2002-12       Impact factor: 4.398

7.  The determination of bone viability: a histochemical method for identification of lactate dehydrogenase activity in osteocytes in fresh calcified and decalcified sections of human bone.

Authors:  S Y Wong; C R Dunstan; R A Evans; E Hills
Journal:  Pathology       Date:  1982-10       Impact factor: 5.306

8.  Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females.

Authors:  R R Recker; D B Kimmel; A M Parfitt; K M Davies; N Keshawarz; S Hinders
Journal:  J Bone Miner Res       Date:  1988-04       Impact factor: 6.741

9.  Age and distance from the surface but not menopause reduce osteocyte density in human cancellous bone.

Authors:  S Qiu; D S Rao; S Palnitkar; A M Parfitt
Journal:  Bone       Date:  2002-08       Impact factor: 4.398

10.  The effect of age on bone composition and viability in the femoral head.

Authors:  S Y Wong; J Kariks; R A Evans; C R Dunstan; E Hills
Journal:  J Bone Joint Surg Am       Date:  1985-02       Impact factor: 5.284

View more
  12 in total

1.  Glucocorticoid-induced osteoporosis: an indication for anabolic therapy.

Authors:  Piet Geusens
Journal:  Curr Osteoporos Rep       Date:  2009-09       Impact factor: 5.096

2.  Osteoblasts play key roles in the mechanisms of action of strontium ranelate.

Authors:  T C Brennan; M S Rybchyn; W Green; S Atwa; A D Conigrave; R S Mason
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

3.  Glucocorticoid-induced osteoporosis: treatment update and review.

Authors:  Lisa-Ann Fraser; Jonathan D Adachi
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

4.  [Local and systemic bone effects of rheumatoid arthritis].

Authors:  M Rauner; L C Hofbauer; M Aringer
Journal:  Z Rheumatol       Date:  2012-12       Impact factor: 1.372

Review 5.  The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis.

Authors:  Núria Guañabens; Laia Gifre; Pilar Peris
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

6.  Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients.

Authors:  Steven W Ing; Loraine T Sinnott; Sirisha Donepudi; Elizabeth A Davies; Ronald P Pelletier; Nancy E Lane
Journal:  Clin Transplant       Date:  2010-10-21       Impact factor: 2.863

7.  Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.

Authors:  C Roux; D M Reid; J-P Devogelaer; K Saag; C S Lau; J-Y Reginster; P Papanastasiou; C Bucci-Rechtweg; G Su; P N Sambrook
Journal:  Osteoporos Int       Date:  2012-03       Impact factor: 4.507

Review 8.  Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity.

Authors:  Robert S Weinstein
Journal:  Bone       Date:  2009-07-08       Impact factor: 4.398

Review 9.  Functional Heterogeneity Within Osteoclast Populations-a Critical Review of Four Key Publications that May Change the Paradigm of Osteoclasts.

Authors:  Neha Sharma; Megan M Weivoda; Kent Søe
Journal:  Curr Osteoporos Rep       Date:  2022-07-15       Impact factor: 5.163

10.  Expression of HCA2 Receptors in Femoral Epiphysis and Metaphysis of Rats with Dexamethasone-Induced Osteoporosis.

Authors:  Tahoora Shomali; Mohammad Kamalpour; Mehdi Fazeli; Alireza Rafati
Journal:  Int J Mol Cell Med       Date:  2016-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.